Intestinal oxalate-regulation pathway

The intestinal oxalate-regulation pathway is a physiological system that manages the flux of oxalate across the intestinal epithelium, playing a vital role in maintaining systemic oxalate homeostasis. This pathway is primarily mediated by members of the solute carrier 26 (SLC26) family, specifically the SLC26A6 exchanger, which facilitates the secretion of oxalate into the gut lumen, and SLC26A3, which is involved in its absorption [Knauf et al., 2011, Journal of the American Society of Nephrology]. The pathway also integrates the metabolic activity of the gut microbiome, where specific bacteria like Oxalobacter formigenes degrade oxalate, thereby reducing the amount available for absorption [Hatch & Freel, 2005, Seminar in Nephrology]. Dysregulation of this pathway, often seen in enteric hyperoxaluria or primary hyperoxaluria, leads to elevated urinary oxalate levels, which can cause recurrent kidney stones and progressive renal damage [NIDDK, 2023]. Pharmacological targeting of this pathway involves the use of oral oxalate-degrading enzymes, such as reloxaliase, which act within the intestinal lumen to break down dietary and endogenous oxalate before it can be absorbed [Hoppe et al., 2017, Journal of Urology]. Additionally, therapeutic strategies may include the administration of probiotics to restore oxalate-degrading bacterial populations or the use of intestinal oxalate binders to prevent absorption. By reducing the intestinal absorption of oxalate, these therapies aim to lower the renal oxalate load and prevent the formation of calcium oxalate crystals in the urinary tract. This pathway represents a significant therapeutic target for patients with various forms of hyperoxaluria who have limited treatment options.

Other names

Intestinal oxalate transport systemEnteric oxalate elimination pathwayGut-kidney axis of oxalate homeostasisIntestinal oxalate secretion pathway

The primary mechanism involves the enzymatic degradation of oxalate within the gastrointestinal tract to prevent its absorption into the bloodstream, as well as the potential modulation of SLC26 transporters to enhance the enteric secretion of systemic oxalate into the gut lumen [Hoppe et al., 2017, Journal of Urology; Knauf et al., 2011, JASN].